As of 2025-05-16, the EV/EBITDA ratio of CASI Pharmaceuticals Inc (CASI) is -1.31. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CASI's latest enterprise value is 28.04 mil USD. CASI's TTM EBITDA according to its financial statements is -21.41 mil USD. Dividing these 2 quantities gives us the above CASI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.1x - 13.5x | 13.3x |
| Forward P/E multiples | 19.0x - 26.2x | 22.6x |
| Fair Price | (26.26) - (18.66) | (24.81) |
| Upside | -1550.9% - -1130.9% | -1470.7% |
| Date | EV/EBITDA |